We wanted to let you know that, after 5 incredible years, the data collection phase of T21 is drawing to a close. We are grateful to the participants who were willing to provide us information on their health and experiences with medical cannabis, without their involvement, none of this would have bene possible. Please uninstall the T21 app if you were taking part in the beta testing.
As we reach the conclusion of T21, we celebrate the successful culmination of one of the largest datasets on medical cannabis ever created in the UK. Designed to gather real-world data on the efficacy and safety of cannabis-based treatments for a range of conditions, including chronic pain, anxiety, and epilepsy, amongst others T21 has enrolled thousands of patients across the country. The insights gathered from this study have contributed to the growing body of evidence supporting the medical use of cannabis in treating a variety of health conditions.
As T21 comes to an end, it marks a pivotal moment in the ongoing evolution of medical cannabis policy and practice in the UK. The data collected will be integral in informing future healthcare guidelines, influencing regulatory frameworks, and guiding both public and clinical attitudes toward cannabis-based treatments. While the project’s data collection conclusion does not signal the end of research in this area, it represents a significant milestone in bridging the gap between scientific inquiry and practical application. The legacy of T21 will undoubtedly shape the future of medical cannabis research and continue to provide crucial insights into its potential benefits for patients in need.
Looking ahead, continued support for T21 is crucial to furthering research, influencing policy, and advocating for patient access. Expanding the registry will deepen our understanding of cannabis's therapeutic potential, while the evidence generated could help drive more progressive medical cannabis policies in the UK. T21 also plays a vital role in patient advocacy, giving those who benefit from cannabis treatments a voice in shaping the future of medical care. To ensure the continuation of this important work, T21 is now offering sponsorship opportunities, and supporters can contact twenty21@drugscience.org.uk to get involved and help advance the project’s goals.
Please uninstall the T21 app.
A huge thank you to our amazing T21 partners— Somaí Pharmaceuticals, Blackpoint Biotech, Ethypharm and 4C Labs—for your incredible support and collaboration throughout this project. Your expertise and dedication have been key to everything we've achieved, and we couldn’t have done it without you. Together, we’ve gathered valuable insights that will help shape the future of cannabis-based treatments, and we’re grateful for your trust in us. We look forward to continuing our work together with other projects and seeing the lasting impact of what we've built as a team.
Source: Email from Drug Science
As we reach the conclusion of T21, we celebrate the successful culmination of one of the largest datasets on medical cannabis ever created in the UK. Designed to gather real-world data on the efficacy and safety of cannabis-based treatments for a range of conditions, including chronic pain, anxiety, and epilepsy, amongst others T21 has enrolled thousands of patients across the country. The insights gathered from this study have contributed to the growing body of evidence supporting the medical use of cannabis in treating a variety of health conditions.
As T21 comes to an end, it marks a pivotal moment in the ongoing evolution of medical cannabis policy and practice in the UK. The data collected will be integral in informing future healthcare guidelines, influencing regulatory frameworks, and guiding both public and clinical attitudes toward cannabis-based treatments. While the project’s data collection conclusion does not signal the end of research in this area, it represents a significant milestone in bridging the gap between scientific inquiry and practical application. The legacy of T21 will undoubtedly shape the future of medical cannabis research and continue to provide crucial insights into its potential benefits for patients in need.
Key Achievements of T21
Since its launch in 2019, T21 has made significant strides in advancing the understanding of medical cannabis, creating one of the largest UK patient registries with over 4,500 individuals suffering from conditions such as chronic pain, anxiety and neurological conditions. This valuable real-world data has not only contributed to several key publications but also provided essential insights into the safety and efficacy of cannabis-based treatments. In addition to building scientific knowledge, T21 has worked to improve access by offering medical cannabis at reduced costs, making treatment more affordable for patients and normalising its use in medical practice. The project has also been instrumental in advocating for policy changes, using patient-reported outcomes to challenge outdated regulations and push for the recognition of medical cannabis as a legitimate and effective treatment option.Looking ahead, continued support for T21 is crucial to furthering research, influencing policy, and advocating for patient access. Expanding the registry will deepen our understanding of cannabis's therapeutic potential, while the evidence generated could help drive more progressive medical cannabis policies in the UK. T21 also plays a vital role in patient advocacy, giving those who benefit from cannabis treatments a voice in shaping the future of medical care. To ensure the continuation of this important work, T21 is now offering sponsorship opportunities, and supporters can contact twenty21@drugscience.org.uk to get involved and help advance the project’s goals.
A heartfelt thank you to our T21 patients
We want to take a moment to thank all of our patients for their invaluable contribution to our study. Your participation and dedication in completing T21 questionnaires every 3 months, have been absolutely essential. Thanks to you, we’ve taken a big step toward making medical cannabis more accessible for the thousands of patients who can benefit from it. We truly appreciate your time and effort in helping us make a difference!Please uninstall the T21 app.
A big thank you to our T21 partners
A huge thank you to our amazing T21 partners— Somaí Pharmaceuticals, Blackpoint Biotech, Ethypharm and 4C Labs—for your incredible support and collaboration throughout this project. Your expertise and dedication have been key to everything we've achieved, and we couldn’t have done it without you. Together, we’ve gathered valuable insights that will help shape the future of cannabis-based treatments, and we’re grateful for your trust in us. We look forward to continuing our work together with other projects and seeing the lasting impact of what we've built as a team.
A final wholehearted thank you to our staff
We want to extend a huge thank you to our incredible staff for all their hard work and dedication on this project. Your passion, expertise, and commitment have been absolutely crucial in bringing this initiative to life. From the long hours to the attention to detail, you’ve all gone above and beyond, and it truly shows in the results. We couldn't have done it without each of you, and we’re so grateful for the energy and care you put into making this project a success.Source: Email from Drug Science
